 "Pharma shares gain; Nifty Pharma index up 5% in three days")
Shares of pharmaceutical companies were trading higher for the third straight trading session, with the Nifty Pharma index gaining more than 5% during the period.
Aurobindo Pharma and Divi’s Laboratories were up 5% each, while Sun Pharmaceutical Industries, Cadila Healthcare, Glenmark Pharmaceuticals, Cipla, Lupin and Dr Reddy’s Laboratories were up in the range of 1% to 3% on the National Stock Exchange (NSE).
Jubilant Life Sciences, Pfizer, SMS Pharma, Marksans Pharma, Ipca Laboratories, Granules India, FDC and Strides Shasun, the non-index pharma stocks were trading higher between 3% and 5%.
At 09:55 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% as compared to 0.02% decline in the Nifty 50 index. In past three trading sessions, it went up 5.3% against 0.2% rise in the benchmark index.
In past two weeks, till Monday, the pharma index tanked 15%, after most of pharmaceutical companies reported a weak set of numbers for the quarter ended March 2017 (Q4FY17), due to continuing increased competition and the challenging pricing environment in the biggest market US. On comparison, the Nifty 50 index had gained 2% during the period.
Nine pharmaceutical companies from the Nifty Pharma index announced their Q4FY17 results, have posted 8.7% year-on-year (Y-o-Y) decline in their aggregate net profit, first time in past seven quarters. The combined net sales of these companies grew single digit by 1.6% YoY, lowest in many quarters.
Aurobindo Pharma has gain 5.7% to Rs 607 on NSE in intra-day trade today. The stock rallied 17% in past three trading sessions, after the company said it believes launches and higher volume will drive growth in US, despite pricing pressure in the base business.
“New launches and a well-diversified portfolio have enabled Aurobindo to deliver steady growth in its US business in FY17, despite the high single-digit price erosion in the base business. Injectable launches will help improve product mix and margins,” analysts at IIFL Institutional Equities said in result update.
Aurobindo Pharma and Divi’s Laboratories were up 5% each, while Sun Pharmaceutical Industries, Cadila Healthcare, Glenmark Pharmaceuticals, Cipla, Lupin and Dr Reddy’s Laboratories were up in the range of 1% to 3% on the National Stock Exchange (NSE).
Jubilant Life Sciences, Pfizer, SMS Pharma, Marksans Pharma, Ipca Laboratories, Granules India, FDC and Strides Shasun, the non-index pharma stocks were trading higher between 3% and 5%.
At 09:55 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% as compared to 0.02% decline in the Nifty 50 index. In past three trading sessions, it went up 5.3% against 0.2% rise in the benchmark index.
In past two weeks, till Monday, the pharma index tanked 15%, after most of pharmaceutical companies reported a weak set of numbers for the quarter ended March 2017 (Q4FY17), due to continuing increased competition and the challenging pricing environment in the biggest market US. On comparison, the Nifty 50 index had gained 2% during the period.
Nine pharmaceutical companies from the Nifty Pharma index announced their Q4FY17 results, have posted 8.7% year-on-year (Y-o-Y) decline in their aggregate net profit, first time in past seven quarters. The combined net sales of these companies grew single digit by 1.6% YoY, lowest in many quarters.
Aurobindo Pharma has gain 5.7% to Rs 607 on NSE in intra-day trade today. The stock rallied 17% in past three trading sessions, after the company said it believes launches and higher volume will drive growth in US, despite pricing pressure in the base business.
“New launches and a well-diversified portfolio have enabled Aurobindo to deliver steady growth in its US business in FY17, despite the high single-digit price erosion in the base business. Injectable launches will help improve product mix and margins,” analysts at IIFL Institutional Equities said in result update.
| Company | 15/05/2017 | 29/05/2017 | % chg | LTP | % chg |
| Aurobindo Pharma | 613.95 | 512.40 | -16.54 | 599.80 | 17.06 |
| Divi's Lab. | 624.25 | 569.50 | -8.77 | 612.50 | 7.55 |
| Glenmark Pharma. | 715.25 | 610.45 | -14.65 | 653.40 | 7.04 |
| Lupin | 1284.50 | 1110.20 | -13.57 | 1177.50 | 6.06 |
| Glaxosmit Pharma | 2429.30 | 2330.55 | -4.06 | 2455.90 | 5.38 |
| Dr Reddy's Labs | 2675.80 | 2425.85 | -9.34 | 2546.05 | 4.95 |
| Cadila Health. | 488.35 | 455.85 | -6.66 | 473.65 | 3.90 |
| Cipla | 569.00 | 505.35 | -11.19 | 523.70 | 3.63 |
| Piramal Enterp. | 2866.25 | 2645.25 | -7.71 | 2736.10 | 3.43 |
| Sun Pharma.Inds. | 654.45 | 502.60 | -23.20 | 516.35 | 2.74 |
| LTP : Last traded price on NSE in Rs at 10:15 am. | |||||
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%